W. Michael Flanagan
CIK 1841990 · Chief Scientific Officer · last filed 2026-09-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10578 SCIENCE CENTER DR., SUITE 125
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNA | Chief Scientific Officer | 31,974 | $8.05 | $257.4K | -$13.50M | 21 | 2026-09-22 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Chief Scientific Officer | 0 | — | — | $0 | 1 | 2026-02-27 |
Recent Filings · Page 2 of 3
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-21 | RNA | Sell (S) | −11,780 | -$365.9K | EDGAR |
| 2025-03-12 | RNA | Mixed | — | -$318.2K | EDGAR |
| 2025-03-11 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −20,000 | -$600.8K | EDGAR |
| 2025-01-23 | RNA | Sell (S) | −5,672 | -$162.2K | EDGAR |
| 2025-01-08 | RNA | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-12-19 | RNA | Sell (S) | −12,742 | -$416.2K | EDGAR |
| 2024-12-13 | RNA | Mixed | — | -$319.1K | EDGAR |
| 2024-12-11 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −24,000 | -$866.4K | EDGAR |
| 2024-10-03 | RNA | Mixed | — | -$1.30M | EDGAR |
| 2024-10-01 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −38,018 | -$1.75M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.